Predictors of fixed-dose combination antihypertensive drug therapy in a Medicaid population

Journal of the American Society of Hypertension

Volumn 2, Issue 6, 2008, Pages 469-475

  Shaya, Fadia T ^a   Du, Dongyi ^a   Frech Tamas, Feride ^b   Lau, Helen ^b   Fatodu, Hugh ^c   Garber, Howard ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

blood pressure; diuretic hydrochlorothiazide; Hypertension; managed care organizations

Indexed keywords

DIURETIC AGENT; ENALAPRIL; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; LISINOPRIL;

ADULT; AGE; ANTIHYPERTENSIVE THERAPY; ARTICLE; COMORBIDITY; CONTROLLED STUDY; FEMALE; HEALTH INSURANCE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MANAGED CARE ORGANIZATION; MEDICAID; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; TREATMENT PLANNING; UNITED STATES;

EID: 57149085270     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2008.04.011     Document Type: Article

References (24)

1. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 289 (2003) 2560-2572 [see comment; erratum appears in JAMA 2003;290:197]
2. Ma J., Lee K.-V., and Stafford R.S. Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension between 1993 and 2004. Hypertension 48 (2006) 846-852
3. Frishman W.H., Bryzinski B.S., Coulson L.R., DeQuattro V.L., Vlachakis N.D., Mroczek W.J., et al. A multifactorial trial design to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide. Arch Intern Med 154 (1994) 1461-1468
4. McGill J.B., and Reilly P.A. Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension. Clin Cardiol 24 (2001) 66-72
5. Chrysant S.G., Weber M.A., Wang A.C., and Hinman D.J. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 17 (2004) 252-259
6. Giles T.D., Bakris G.L., Smith D.H.G., Davidai G., and Weber M.A. Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial. Am J Hypertens 16 (2003) 460-466
7. Kochar M., Guthrie R., Triscari J., Kassler-Taub K.M., and Reeves R.A. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 12 (1999) 797-805
8. Jamerson K., Bakris G.L., Dahlof B., Pitt B., Velazquez E., Gupte J., et al. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press 16 (2007) 80-86
9. Mancia G., Omboni S., and Grassi G. Combination treatment in hypertension: the VeraTran Study. Am J Hypertens 10 (1997) 153S-158S
10. Dezii C.M. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Managed Care 10 (2001) 6-10
11. Cushman W.C., Reda D.J., Perry H.M., Williams D., Abdellatif M., and Materson B.J. Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med 160 (2000) 825-831
12. Sudano Jr. J.J., and Baker D.W. Antihypertensive medication use in Hispanic adults: a comparison with black adults and white adults. Med Care 39 (2001) 575-587
13. Schauer D.P., Johnston J.A., Moomaw C.J., Wess M., and Eckman M.H. Racial disparities in the filling of warfarin prescriptions for nonvalvular atrial fibrillation. Am J Med Sci 333 (2007) 67-73
14. Knudsen H.K., Ducharme L.J., and Roman P.M. Racial and ethnic disparities in SSRI availability in substance abuse treatment. Psychiatric Servi 58 (2007) 55-62
15. Van Houtven C.H., Voils C.I., Oddone E.Z., Weinfurt K.P., Friedman J.Y., Schulman K.A., et al. Perceived discrimination and reported delay of pharmacy prescriptions and medical tests. J Gen Intern Medi 20 (2005) 578-583
16. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987) 373-383
17. Martinez-Castelao A., Gorriz J.L., Garcia-Lopez F., Lopez-Revuelta K., de Alvaro F., and Cruzado J.M. Perceived health-related quality of life and comorbidity in diabetic patients starting dialysis (CALVIDIA Study). J Nephrol 17 (2004) 544-551
18. Glynn R.J., Knight E.L., Levin R., and Avorn J. Paradoxical relations of drug treatment with mortality in older persons. Epidemiology 12 (2001) 682-689
19. Taylor A.A., and Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Congest Heart Fail 9 (2003) 324-332
20. Bangalore S., Kamalakkannan G., Parkar S., and Messerli F.H. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 120 (2007) 713-719
21. Impact of combination therapy on managed care. Based on a presentation by Lisa Latts, MD, MSPH. Am J Managed Care 5 (1999) S456-S460 discussion S460-2
22. The impact of fixed-dose combinations on blood pressure control, persistence, and comorbid disease. Am J Managed Care (2006) 7-9
23. Carter B.L. Antihypertensive prescribing: do we have reason to celebrate?. Hypertension 48 (2006) 816-817
24. Cheung B., Ong K., Man Y., Lam K., and Lau C. Prevalence, awareness, treatment, and control of hypertension: United States National Health and Nutrition Examination Survey, 2001-2002. J Clin Hypertens 8 (2006) 93-98